COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura

We present a 62-year-old gentleman with history of Crohn’s disease, G6PD deficiency, who presented with immune-mediated thrombotic thrombocytopenia purpura (iTTP) one week after the diagnosis of COVID-19 infection. He was admitted with worsening dyspnea, acute renal failure, and profound thrombocyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhomoud, Mohammad, Alhobayb, Tamara, Armitage, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383479/
https://www.ncbi.nlm.nih.gov/pubmed/34458098
http://dx.doi.org/10.1016/j.idcr.2021.e01256
_version_ 1783741746528649216
author Alhomoud, Mohammad
Alhobayb, Tamara
Armitage, Keith
author_facet Alhomoud, Mohammad
Alhobayb, Tamara
Armitage, Keith
author_sort Alhomoud, Mohammad
collection PubMed
description We present a 62-year-old gentleman with history of Crohn’s disease, G6PD deficiency, who presented with immune-mediated thrombotic thrombocytopenia purpura (iTTP) one week after the diagnosis of COVID-19 infection. He was admitted with worsening dyspnea, acute renal failure, and profound thrombocytopenia with marked schistocytosis on peripheral smear. ADAMTS13 level was severely deficient. He was treated with oral prednisone, plasma exchange and rituximab with complete clinical resolution. Given the temporal association of this recurrent episode of iTTP with COVID-19 infection and no other discernible cause, COVID-19 infection was the most likely trigger.
format Online
Article
Text
id pubmed-8383479
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83834792021-08-24 COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura Alhomoud, Mohammad Alhobayb, Tamara Armitage, Keith IDCases Article We present a 62-year-old gentleman with history of Crohn’s disease, G6PD deficiency, who presented with immune-mediated thrombotic thrombocytopenia purpura (iTTP) one week after the diagnosis of COVID-19 infection. He was admitted with worsening dyspnea, acute renal failure, and profound thrombocytopenia with marked schistocytosis on peripheral smear. ADAMTS13 level was severely deficient. He was treated with oral prednisone, plasma exchange and rituximab with complete clinical resolution. Given the temporal association of this recurrent episode of iTTP with COVID-19 infection and no other discernible cause, COVID-19 infection was the most likely trigger. Elsevier 2021-08-24 /pmc/articles/PMC8383479/ /pubmed/34458098 http://dx.doi.org/10.1016/j.idcr.2021.e01256 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Alhomoud, Mohammad
Alhobayb, Tamara
Armitage, Keith
COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura
title COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura
title_full COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura
title_fullStr COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura
title_full_unstemmed COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura
title_short COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura
title_sort covid-19 infection triggering thrombotic thrombocytopenic purpura
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383479/
https://www.ncbi.nlm.nih.gov/pubmed/34458098
http://dx.doi.org/10.1016/j.idcr.2021.e01256
work_keys_str_mv AT alhomoudmohammad covid19infectiontriggeringthromboticthrombocytopenicpurpura
AT alhobaybtamara covid19infectiontriggeringthromboticthrombocytopenicpurpura
AT armitagekeith covid19infectiontriggeringthromboticthrombocytopenicpurpura

Ejemplares similares